Tchang Beverly G, Knight Michael G, Adelborg Kasper, Clements Jennifer N, Iversen Aske Thorn, Traina Andrea
Weill Cornell Medicine, New York, New York, USA.
The George Washington University, Washington, DC, USA.
Obesity (Silver Spring). 2025 Feb;33(2):267-277. doi: 10.1002/oby.24202. Epub 2025 Jan 5.
The objective of this study was to assess antihypertensive and lipid-lowering treatment changes in participants receiving semaglutide 2.4 mg versus placebo across pooled populations from five Semaglutide Treatment Effect in People with Obesity (STEP) trials.
Efficacy and safety of semaglutide 2.4 mg were evaluated in the STEP clinical trials. In this post hoc analysis, STEP 1, 3, 6, and 8 (which included people with overweight or obesity) and, separately, STEP 2 and 6 (which included people with overweight or obesity and type 2 diabetes) were pooled for analysis. Changes in antihypertensive or lipid-lowering treatment intensity from randomization to end of treatment were evaluated.
In both pooled samples, a higher proportion of participants in the semaglutide 2.4 mg group versus placebo underwent antihypertensive or lipid-lowering treatment intensity reduction by end of treatment. A smaller proportion underwent antihypertensive or lipid-lowering treatment intensification by end of treatment in the semaglutide 2.4 mg group of both samples versus placebo. In participants receiving antihypertensive or lipid-lowering medications in both samples, greater numeric reductions in body weight were observed in the semaglutide 2.4 mg group versus placebo.
These results support a relationship between semaglutide 2.4 mg treatment of overweight and obesity and reduced need for antihypertensive and lipid-lowering treatment, facilitating treatment intensity reduction/discontinuation and abating treatment intensification.
本研究的目的是评估在五项司美格鲁肽治疗肥胖人群的疗效（STEP）试验的汇总人群中，接受2.4毫克司美格鲁肽与安慰剂治疗的参与者的降压和降脂治疗变化。
在STEP临床试验中评估了2.4毫克司美格鲁肽的疗效和安全性。在这项事后分析中，将STEP 1、3、6和8（包括超重或肥胖人群）以及分别的STEP 2和6（包括超重或肥胖以及2型糖尿病患者）进行汇总分析。评估从随机分组到治疗结束时降压或降脂治疗强度的变化。
在两个汇总样本中，与安慰剂组相比，司美格鲁肽2.4毫克组中在治疗结束时降低降压或降脂治疗强度的参与者比例更高。在两个样本的司美格鲁肽2.4毫克组中，与安慰剂组相比，在治疗结束时进行降压或降脂治疗强化的参与者比例更小。在两个样本中接受降压或降脂药物治疗的参与者中，与安慰剂组相比，司美格鲁肽2.4毫克组的体重数值下降幅度更大。
这些结果支持2.4毫克司美格鲁肽治疗超重和肥胖与降低降压和降脂治疗需求之间的关系，有助于降低治疗强度/停药并减少治疗强化。
